VivoSeq
Other

Prostatectomy

0

Pipeline Programs↗

14

Active Trials↗

9

Companies Involved↗

Prostatectomy is an early-stage landscape with 0 programs across 9 companies. The most active players are Sanofi, Pfizer, Bayer.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

77/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalS

SURGE Therapeutics

0 programs

PreclinicalEisai logo

Eisai

0 programs

PreclinicalPacira Pharmaceuticals, Inc logo

Pacira Pharmaceuticals, Inc

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

66

clinical trials

Completed33 · 50%
Unknown status9 · 14%
Active, not recruiting9 · 14%
Terminated5 · 8%
Recruiting5 · 8%
Withdrawn4 · 6%
Other1 · 2%

Clinical Trials

Trial Activity

66 trials

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
Recruiting·SSURGE Therapeutics·Phase 1·NCT06450106·18 enrolled
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
Recruiting·—·Phase 3·NCT07427043·300 enrolled
AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
Recruiting·HHackensack Meridian Health·Phase 2/3·NCT04263025·100 enrolled
A Randomized Non-Inferiority Trial Comparing Two Training Modalities for Achieving Proficiency in Robot-Assisted Radical Prostatectomy
Recruiting·—·Preclinical·NCT07669974·56 enrolled
A Pivotal Study of Voro Urologic Scaffold for the Treatment of Post Prostatectomy Stress Urinary Incontinence (ARID II)
Recruiting·LLevee Medical, Inc.·Phase 3·NCT06873581·266 enrolled
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00329043·64 enrolled
Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy
Active, not recruiting·IInsel Gruppe AG, University Hospital Bern·N/A·NCT05746806·36 enrolled
Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy
Active, not recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT03080116·90 enrolled
Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy
Active, not recruiting·UUniversity of Miami·Phase 2·NCT05842057·118 enrolled
Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.
Active, not recruiting·UUNICANCER·Phase 3·NCT01442246·700 enrolled
Trial of Modifications to Radical Prostatectomy
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT01407263·3,204 enrolled
Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy
Active, not recruiting·UUNICANCER·Phase 2·NCT01994239·120 enrolled
Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy
Active, not recruiting·—·Phase 2·NCT04053842·45 enrolled
Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
Active, not recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 1/2·NCT04430192·20 enrolled
A Phase II Trial of Adjuvant Docetaxel in Patients At High Risk of Relapse Following Prostatectomy
Completed·Sanofi logoSanofi·Phase 2·NCT00069888·83 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)